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Association between chemerin, 
omentin-1 and risk of heart failure 
in the population-based EPIC-
Potsdam study
Juliane Menzel  1,2,3,4, Romina di Giuseppe5, Ronald Biemann6, Clemens Wittenbecher1,4, 
Krasimira Aleksandrova7,8, Fabian Eichelmann  7,8, Andreas Fritsche4,9, Matthias B. Schulze1,4, 
Heiner Boeing8, Berend Isermann6 & Cornelia Weikert2,3
The adipokines chemerin and omentin-1 have been suggested to influence cardiovascular function. The 
study aimed to investigate the longitudinal association between chemerin, omentin-1 concentrations 
and risk of incident heart failure (HF), respectively. We conducted a case-cohort study nested within 
the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort (n = 27548) 
including a randomly drawn subsample and all incident HF cases during a mean follow-up of 8.2 ± 1.5 
years. A total of 212 incident HF cases and 2168 individuals free of HF cases were included in the study. 
After multivariable adjustment for established cardiovascular risk factors chemerin was strongly 
associated with risk of HF (HR per doubling chemerin: 4.91; 95%-CI: 2.57–9.39; p < 0.0001). Omentin-1 
was not significantly related to HF risk in the overall study population. However, the association 
between omentin-1 and HF risk was modified by prevalent coronary heart disease (CHD), showing that 
the shape of the association was linear in participants without prevalent CHD (HR doubling omentin-1: 
2.11; 95%-CI: 1.36–3.27; p linear = 0.0009) and U-shaped in participants with pre-existing CHD (p non-
linear = 0.006). Our study provides first evidence for a strong positive association between chemerin 
and risk of HF. The association between the adipokine omentin-1 and risk of HF may differ according to 
pre-existing CHD.
Heart failure (HF) is a complex syndrome with growing public health burden, characterized by frequent hospi-
talization and reduced quality of life1. In spite of improved therapeutic treatments, HF is still a leading cause of 
death globally2. The pathophysiology of HF is complex, however independent risk factors have been identified, 
foremost coronary heart disease (CHD), as well as hypertension, diabetes and obesity2,3. The discovery of adi-
pokines identified adipose tissue as an important key factor in the organ crosstalk network4, including cardiovas-
cular function5,6. Nowadays, it has been suggested that chemerin and omentin-1 may be suitable candidates to 
influence cardiovascular health.
Chemerin, also known as TIG2 (tazarotene-induced gene 2) or RARRES2 (retinoic acid receptor responder 
protein 2) is mainly produced in adipose tissue and in the liver7. It has been shown that circulating chemerin 
concentrations were associated with the higher presence of coronary artery disease (CAD)8–12 and severity of cor-
onary atherosclerosis8,9,12. Moreover, high chemerin concentrations were independently associated with arterial 
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stiffness13, and with carotid artery plaque instability14. Recently, Leiherer et al. observed an association between 
higher chemerin concentrations and higher risk of further cardiovascular events in patients with established or 
suspected stable CAD in a prospective study15. Indeed, scientific evidence proposed chemerin as a biomarker with 
adverse effects on cardiovascular health, however less is known about chemerin and risk of HF.
Omentin-1 is a novel adipokine primarily released from visceral adipose tissue16. So far, conflicting results 
were reported from studies investigating the association between omentin-1 and different cardiovascular end-
points. On the one hand studies promoted omentin-1 as cardio-protective adipokine, showing cross-sectional 
associations of omentin-1 with several cardiometabolic parameters e.g. inverse association between omentin-1 
and carotid artery intima-media thickness in patients with metabolic syndrome17 and decreased omentin-1 
associated with cardiovascular dysfunction in patients with type 2 diabetes18. On the other hand prospective 
studies suggested omentin-1 as cardiovascular risk factor19,20 e.g. our previous study performed in the European 
Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study showed that higher omentin-1 con-
centrations were associated with a higher risk of stroke, particular in metabolically healthy participants (e.g. 
normal waist circumference, low C-reactive protein concentrations)19. Interestingly, a recently published study 
noticed that higher omentin-1 concentrations were related to increased left ventricular volumes and dysfunction 
in patients with chronic HF16,21. The latter may in particular suggest an involvement of omentin-1 in the patho-
genesis of HF.
Up to now, studies investigating the relationship between chemerin, omentin-1 and HF incidence are still 
missing. Therefore, the present prospective study aimed to investigate the longitudinal association between circu-
lating chemerin and omentin-1 concentrations and the risk of HF in the population-based EPIC-Potsdam study. 
Further we aimed to investigate possible effect modifications of important risk factors for HF i.e. sex, obesity, 
inflammation and the prevalent diseases diabetes, hypertension and CHD.
Results
General and biochemical characteristics. Medians and interquartile ranges of chemerin and omentin-1 
were 147.3 ng/ml (125.3–170.5) and 397.8 ng/ml (327.7–489.5) in the subcohort and 180.0 ng/ml (156.1–206.2) 
and 452.6 ng/ml (368.9–569.7) in HF cases. The distribution (sex- and age-adjusted mean (95%-CI) or percent-
age) of general and biochemical baseline characteristics according to quartiles of chemerin and omentin-1 across 
the subcohort are shown in Table 1 and Table 2. Participants with higher chemerin concentrations have higher 
waist circumference (1. quartile (Q1): 81.8 (80.9–82.6) cm vs. 4. quartile (Q4): 93.6 (92.7–94.4) cm; p for trend 
< 0.0001), and were more likely to suffer from prevalent diabetes (Q1: 3.8% vs. Q4: 7.6%; p for trend = 0.003), 
metabolic syndrome (Q1: 29.8% vs. Q4: 64.4%; p for trend < 0.0001), or hypertension (Q1: 38.3% vs. Q4: 63.4%; 
p for trend < 0.0001). The blood-based biomarker concentrations of total cholesterol, triglycerides and high sen-
sitivity C-reactive protein (hsCRP) were on average higher in participants with higher chemerin level (all p for 
trend < 0.0001). Moreover, we observed inverse associations across quartiles of chemerin with high density lipo-
protein (HDL)-cholesterol and omentin-1 (all p for trend < 0.05) (Table 1). In contrast, participants with higher 
omentin-1 concentrations have lower waist circumference (Q1: 89.8 (88.9–90.7) cm vs. Q4: 85.2 (84.3–86.1) cm; 
p for trend < 0.0001) and were more likely to have a history of prevalent CHD (Q1: 8.0% vs. Q4: 11.1%; p for 
trend = 0.04). Further, omentin-1 showed a significant positive association with HDL-cholesterol, a significant 
inverse association was observed with hsCRP (all p for trend < 0.05) (Table 2). Furthermore, in Supplementary 
Table S1 Spearman sex- and age-adjusted partial correlation coefficients on the associations of chemerin and 
omentin-1 in relation to general and biochemical baseline characteristics are presented, and in Supplementary 
Table S2 the clinical characteristics of HF cases are summarized.
Chemerin and the risk of HF. After adjustment for age and sex participants in the highest quartile of 
chemerin concentrations had a higher risk of HF (Model 1, HR: 9.47; 95%-confidence interval (CI): 4.67–19.2; 
p linear trend < 0.0001) compared to participants in the lowest quartile (Table 3). After additionally adjustment 
for waist circumference, physical activity, education, smoking, alcohol consumption, prevalent hypertension, 
diabetes, CHD, HDL-cholesterol, total cholesterol, triglycerides and hsCRP (Model 4) the association was atten-
uated, but a strong and significant association remained (HR: 4.23; 95%-CI: 1.92–9.35 for the highest quartile 
compared to the lowest quartile, p linear trend < 0.0001, Table 3). There was no evidence of departure from 
linearity for the relation between chemerin and HF risk (p for nonlinearity = 0.41). Interaction analyses revealed 
no differences in the association between chemerin and risk of HF with respect to sex (p for interaction = 0.97), 
waist circumference (p for interaction = 0.60), prevalent CHD (p for interaction = 0.36), prevalent diabetes (p for 
interaction = 0.89), prevalent hypertension (p for interaction = 0.20) or hsCRP (p for interaction = 0.98).
Omentin-1 and the risk of HF. The present study observed no association between omentin-1 and the risk 
of HF in the overall study population (Model 4, HR per doubling omentin-1:1.25; 95%-CI: 0.80–1.96, p = 0.32) 
(Supplementary Table S3). However, the association between omentin-1 and HF risk was modified by prevalent 
CHD (p for interaction = 0.0005) (Fig. 1). Stratified analyses, conducted in the fully adjusted Model 4, revealed 
a positive linear association of omentin-1 with the risk of HF (HR doubling omentin-1: 2.11; 95%-CI: 1.36–
3.27; p linear = 0.0009) in participants without prevalent CHD (n = 2140 (including 140 HF cases). Accordingly, 
for the second to the fourth quartile of omentin-1 in comparison to the first quartile (reference) the present 
study observed HRs (95%-CI) of 1.40 (0.74–2.63), 1.67 (0.87–3.18), 2.16 (1.19–3.93), respectively (p linear 
trend = 0.008). In contrast, in participants with prevalent CHD at baseline a U-shaped association between 
omentin-1 and HF risk was observed (n = 240 (including 72 HF cases), p non-linear = 0.006, Fig. 1) with the 
following HRs (95%-CI) 1. Quartile: 4.94 (1.76–13.9), 2. Quartile: 2.49 (0.89–7.13), 3. Quartile: reference, 4. 
Quartile: 1.48 (0.59–3.68). No further interaction in the overall study population (Model 4) was observed between 
omentin-1 and sex, (p for interaction = 0.46), waist circumference (p for interaction = 0.06), prevalent diabetes (p 
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for interaction = 0.20), prevalent hypertension (for interaction = 0.53) or hsCRP (p for interaction = 0.41) with 
respect to HF.
Sensitivity analyses. All sensitivity analyses have been conducted in the fully adjusted model 4. After 
exclusion of cases that occurred during the first 2 years of follow-up (n = 2335) from the analysis the associa-
tions between chemerin (HR per doubling chemerin: 4.89; 95%-CI: 2.49–9.61; p < 0.0001) and omentin-1 (HR 
per doubling omentin-1: 1.39; 95%-CI: 0.90–2.13; p = 0.14) concentrations and the risk of HF in the overall 
population remained unaltered. Also, results from stratified analyses did not considerably changed. Regarding 
omentin-1, the association was modified by prevalent CHD (p for interaction = 0.02), showing a linear associ-
ation in participants without prevalent CHD (p linear = 0.003) and a U-shaped association in participants with 
prevalent CHD (p non-linear = 0.007). Moreover, also after excluding probable and possible HF cases (n = 2317) 
from the analysis the associations of both chemerin (HR per doubling chemerin: 3.95; 95%-CI: 1.82–8.58; 
p = 0.0005) and omentin-1 (HR per doubling omentin-1: 1.14; 95%-CI: 0.65–1.98; p = 0.65) and the risk of HF 
remained unchanged. Further adjustment for N-terminal pro-brain natriuretic peptide (NT-proBNP) (n = 1346) 
did not substantially alter the risk estimates as follows: chemerin was strongly associated with HF risk (HR per 
doubling chemerin: 5.36; 95%-CI: 2.52–11.4; p < 0.0001) and omentin-1 was not significantly related to HF in the 
overall study population (HR doubling omentin-1:1.24; 95%-CI: 0.80–1.93; p = 0.33). Also results from stratified 
analyses did not considerably change when further adjustment for NT-proBNP was considered. The association 
between omentin-1 and the risk of HF was modified by prevalent CHD (p for interaction = 0.004), showing that 
the shape of the association was linear in participants without prevalent CHD (p linear = 0.009) and U-shaped in 
participants with prevalent CHD (p non-linear = 0.0001).
Characteristics
Quartiles of chemerin in the subcohorta P for 
trendQ1 Q2 Q3 Q4
n 545 550 548 547
Chemerin [ng/ml]b 111.7 (101.8–119.3) 136.9 (131.1–141.6) 157.8 (152.0–163.6) 191.9 (180.2–208.8)
Men [%]c 42.2 40.8 38.7 33.5 0.003
Age [years]c 47.1 (46.4–47.9) 50.6 (49.9–51.3) 51.2 (50.4–51.9) 54.0 (53.3–54.8) <0.0001
Waist circumference [cm] 81.8 (80.9–82.6) 85.7 (84.8–86.5) 88.6 (87.8–89.4) 93.6 (92.7–94.4) <0.0001
Physical activity [h/week] 1.3 (1.2–1.5) 1.0 (0.8–1.1) 1.0 (0.8–1.1) 0.8 (0.7–1.0) <0.0001
Smoking [%]
  Non-Smoker 47.4 44.4 41.7 40.0 0.008
  Ex-Smoker 34.4 34.8 34.6 35.5 0.72
  Smoker < 20 cigarettes/day 13.4 14.6 16.1 16.8 0.10
  Smoker ≥ 20 cigarettes/day 4.8 6.1 7.7 7.7 0.02
Education [%]
  Unskilled or skilled 32.7 35.6 36.8 39.1 0.03
  Technical College 22.7 21.4 24.6 22.8 0.70
  University degree 44.5 43.1 38.6 38.1 0.01
Alcohol consumption [%]
  Never 0.6 0.7 0.1 0.1 0.13
  Ex-Drinker 3.0 3.0 2.2 2.0 0.24
  Current (≤12 g women /≤24 g 
men) 65.2 68.6 68.0 71.9 0.03
  Current (>12 g women />24 g 
men) 31.2 27.7 29.6 26.0 0.11
Prevalent diabetes [%] 3.8 3.4 4.4 7.6 0.003
Prevalent hypertension [%] 38.3 47.7 53.6 63.4 <0.0001
Prevalent CHD [%] 7.1 9.1 7.7 10.2 0.13
Prevalent metabolic syndrome 
[%]d 29.8 42.0 50.4 64.4 <0.0001
Total cholesterol [mmol/l] 5.08 (4.99–5.17) 5.20 (5.11–5.29) 5.34 (5.25–5.43) 5.55 (5.46–5.64) <0.0001
HDL-cholesterol [mmol/l] 1.50 (1.47–1.54) 1.45 (1.42–1.48) 1.38 (1.35–1.41) 1.34 (1.30–1.37) <0.0001
Triglyceride [mmol/l] 1.17 (1.09–1.26) 1.46 (1.38–1.54) 1.68 (1.60–1.76) 2.03 (1.94–2.11) <0.0001
hsCRP [mg/l] 0.70 (0.41–0.98) 1.47 (1.19–1.75) 2.20 (1.92–2.48) 3.60 (3.31–3.88) <0.0001
Adiponectin [μg/ml]e 9.02 (8.69–9.35) 8.46 (8.14–8.78) 7.71 (7.39–8.03) 7.25 (6.92–7.58) <0.0001
Omentin-1 [ng/ml] 436.3 (424.7–447.9) 414.7 (403.4–426.1) 417.7 (406.3–429.1) 414.8 (403.1–426.4) 0.02
Table 1. General and biochemical characteristics according to quartiles of chemerin within the subcohort 
(n = 2190) of EPIC-Potsdam study. aAll variables were adjusted for sex and age; expressed as adjusted 
percentage or mean and 95%-CI. bUnadjusted variable, expressed as median (interquartile range). cAdjusted for 
sex, age; according to examined variable. dn = 2153. en = 2188.
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Discussion
In this prospective analysis, we observed a strongly increased risk of HF in participants with high circulating 
chemerin concentrations at baseline. Participants in the fourth quartile of chemerin had a more than fourfold 
higher HF risk. However, omentin-1 was not related to HF risk in the overall study population. Interestingly, the 
association between omentin-1 and risk of HF differed according to the presence of CHD. The shape of the asso-
ciation between omentin-1 and HF risk was linear in participants without prevalent CHD, whereas a U-shaped 
association between omentin-1 and HF incidence was suggested in participants with prevalent CHD.
To our knowledge, this is the first prospective study investigating potential associations between chemerin and 
risk of HF in apparently healthy middle aged men and women. So far, only few studies investigated the association 
between chemerin and different cardiovascular endpoints i.e. one small prospective study investigated the asso-
ciation between chemerin and cardiovascular endpoints in 495 patients undergoing coronary angiography for 
the evaluation of established or suspected stable CAD, showing that patients with high chemerin concentrations 
were more often affected by cardiovascular events, defined by vascular deaths, non-fatal myocardial infarctions, 
non-fatal strokes, and the necessity of cardiovascular intervention15. Moreover it has been demonstrated that the 
expressions of chemerin mRNA and protein was higher in epicardial adipose tissue from patients with CAD22. 
Further, recent studies have shown that circulating serum chemerin concentrations were associated with the 
presence of CAD8–12 and severity of coronary atherosclerosis8,9,12. Despite that the mechanisms of chemerin and 
cardiovascular pathologies have not been investigated thoroughly so far23, a recent study by Rodríguez-Penas et 
al. proposed possible chemerin-related pathways on viability in murine cardiomyocytes7. Observations of this 
study may provide possible explanation for the strong association between higher chemerin concentrations and 
HF risk in the present study. First, Rodríguez-Penas et al. observed that chemerin induced apoptosis directly 
in cultured cardiomyocytes in a dose- and time-dependent manner7. Second, it has been shown that chemerin 
partially suppresses AKT (protein kinase B) phosphorylation at Thr308, which has been linked to apoptosis7. 
Third, it has been demonstrated that chemerin also increased the activity of caspase-9, which could have a direct 
Characteristics
Quartiles of omentin-1 in the subcohorta P for 
trendQ1 Q2 Q3 Q4
n 547 549 548 546
Omentin-1 [ng/ml]b 286.5 (250.6–308.9) 365.4 (346.3–381.6) 441.8 (422.2–465.2) 574.2 (523.0–643.5)
Men [%] c 42.0 39.7 37.6 35.9 0.03
Age [years]c 47.6 (46.9–48.3) 49.1 (48.4–49.8) 52.1 (51.4–52.8) 54.2 (53.5–54.9) <0.0001
Waist circumference [cm] 89.8 (88.9–90.7) 87.4 (86.5–88.3) 86.8 (85.9–87.7) 85.2 (84.3–86.1) <0.0001
Physical activity [h/week] 0.91 (0.76–1.05) 0.92 (0.78–1.07) 0.97 (0.82–1.11) 1.29 (1.14–1.43) 0.0006
Smoking [%]
  Non-Smoker 43.2 42.7 40.8 47.0 0.32
  Ex-Smoker 34.3 34.1 37.3 33.6 0.90
  Smoker < 20 cigarettes/day 15.7 15.5 16.9 12.7 0.28
  Smoker ≥ 20 cigarettes/day 6.8 7.7 5.1 6.7 0.52
Education [%]
  Unskilled or skilled 35.8 35.6 36.4 36.4 0.79
  Technical College 23.0 23.6 24.1 20.7 0.44
  University degree 41.2 40.8 39.5 43.0 0.67
Alcohol consumption [%]
  Never 0.4 0.3 0.3 0.6 0.77
  Ex-Drinker 2.1 2.9 2.7 2.4 0.87
  Current (≤12 g women/≤24 g men) 72.0 68.3 69.5 63.8 0.009
  Current (>12 g women />24 g men) 25.4 28.5 27.5 33.3 0.01
Prevalent diabetes [%] 4.6 3.9 4.6 6.2 0.19
Prevalent hypertension [%] 52.3 50.0 48.9 51.2 0.63
Prevalent CHD [%] 8.0 6.7 8.3 11.1 0.04
Prevalent metabolic syndrome [%]d 50.2 46.2 44.5 44.9 0.06
Total cholesterol [mmol/l] 5.23 (5.14–5.32) 5.30 (5.21–5.39) 5.28 (5.19–5.37) 5.35 (5.26–5.45) 0.09
HDL-cholesterol [mmol/l] 1.35 (1.32–1.38) 1.39 (1.36–1.42) 1.41 (1.38–1.44) 1.52 (1.49–1.55) <0.0001
Triglyceride [mmol/l] 1.63 (1.54–1.72) 1.54 (1.46–1.63) 1.67 (1.58–1.75) 1.48 (1.39–1.57) 0.10
hsCRP [mg/l] 2.54 (2.25–2.83) 1.69 (1.40–1.98) 1.95 (1.66–2.25) 1.70 (1.41–2.00) 0.001
Adiponectin [μg/ml]e 7.00 (6.68–7.32) 7.78 (7.45–8.10) 8.28 (7.96–8.60) 9.44 (9.11–9.77) <0.0001
Chemerin [ng/ml] 152.8 (149.9–155.7) 146.7 (143.9–149.6) 152.4 (149.5–155.3) 148.1 (145.1–151.0) 0.21
Table 2. General and biochemical characteristics according to quartiles of omentin-1 within the subcohort 
(n = 2190) of EPIC-Potsdam study. aAll variables were adjusted for sex and age; expressed as adjusted 
percentage or mean and 95%-CI. bUnadjusted variable, expressed as median (interquartile range). cAdjusted for 
sex, age; according to examined variable. dn = 2153. en = 2188.
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implication in cardiomyocyte apoptosis through the activation of apoptotic mediators of the AKT pathway7. 
Indeed, apoptosis plays a decisive role in the development of HF7,24. In humans, an apoptosis rate ranging from 
0.12% to 0.70% in failing hearts has been reported7,24. Interestingly, this small level of apoptosis is considered 
sufficient to cause HF and even very low levels of apoptosis (23 myocytes/105 nuclei) have been detected to induce 
dilated cardiomyopathy and HF7,24. Given the strong association between chemerin and HF risk in the present 
study, it is possible to speculate that chemerin might cause cardiomyocyte apoptosis leading to HF.
Regarding omentin-1, the present study is the first prospective study investigating associations with risk of 
HF in apparently healthy participants. Former studies investigating the association between omentin-1 and dif-
ferent clinical intermediate cardiovascular phenotypes observed conflicting results. A possible reason for the 
Quartiles of chemerin levels p for 
trend
Per doubling of chemerin
Q1 Q2 Q3 Q4 p-value
Chemerin [ng/ml]a 111.7 (101.8–119.3) 136.9 (131.1–141.6) 157.8 (152.0–163.6) 191.9 (180.2–208.8)
Subcohort participants (n) 545 550 548 547
Heart failure cases (n) 9 24 52 127
Model 1b Reference 2.14 (0.97–4.72) 4.27 (2.06–8.84) 9.47 (4.67–19.2) <0.0001 10.4 (6.39–16.8) <0.0001
Model 2c Reference 1.77 (0.78–3.99) 3.23 (1.49–7.02) 6.43 (3.02–13.7) <0.0001 7.20 (4.20–12.3) <0.0001
Model 3d Reference 1.66 (0.74–3.75) 3.33 (1.53–7.25) 6.27 (2.96–13.3) <0.0001 6.39 (3.65–11.2) <0.0001
Model 4e Reference 1.50 (0.65–3.44) 2.49 (1.12–5.57) 4.23 (1.92–9.35) <0.0001 4.91 (2.57–9.39) <0.0001
Table 3. Hazard ratios of HF according to quartiles of chemerin. Hazard ratios and 95%-CI were derived from 
Cox proportional hazard regression. aQuartiles are based on the distribution of chemerin within the subcohort 
expressed as median and interquartile range. bModel 1: adjusted for age and sex. cModel 2: additionally adjusted 
for waist circumference, physical activity, education, smoking, alcohol consumption. dModel 3: additionally 
adjusted prevalent hypertension, diabetes, CHD. eModel 4: additionally adjusted HDL-cholesterol, total 
cholesterol, triglycerides, hsCRP.
Figure 1. Hazard rate ratio curves for the association between omentin-1 concentrations and the risk of 
heart failure. (a) In participants without prevalent coronary heart disease (n = 2140). (b) In participants with 
prevalent coronary heart disease (n = 240). The solid lines indicate HR of HF as obtained by restricted cubic 
spline Cox regression with knots placed at fixed values (5th, 35th, 50th (reference), 65th, and 95th percentile of 
omentin-1 in the entire case-cohort). Dashed lines indicate 95%-CI. Adjusted for age, sex, waist circumference, 
physical activity, education, smoking, alcohol consumption, prevalent hypertension, diabetes, HDL-cholesterol, 
total cholesterol, triglycerides, hsCRP. P for non-linearity was calculated by Wald chi-square test.
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controversy might be explained by the fact that the suggested cardio-protective associations of omentin-1 were 
mainly based on small studies performed in participants with existing diseases and possibly unfavorable cardi-
ometabolic risk profile17,18,25. We may hypothesize that the role of omentin-1 in cardiovascular health probably 
differs between participants with preexisting metabolic disease or unfavorable metabolic conditions compared to 
apparently healthy individuals. In line with that, we observed in the present study different shapes of associations 
of omentin-1 and risk of HF dependent on the absence or presence of prevalent CHD. In participants without 
prevalent CHD the HF risk rose linear with higher plasma omentin-1 concentrations. In contrast a U-shaped 
relationship between omentin-1 and HF risk was observed in participants with prevalent CHD. Our previous 
study investigating the association between omentin-1 and the risk of stroke performed in an apparently healthy 
population strengthen our hypothesis, by showing that stroke risk was generally stronger in metabolically health-
ier individuals compared to high cardiovascular risk groups19. In detail, the association between omentin-1 and 
the risk of stroke was stronger in participants with normal waist circumference, low concentrations of triglyceride 
and hsCRP, high adiponectin concentrations or absence of metabolic syndrome compared to those with increased 
waist circumference, high concentrations of triglycerides and hsCRP, low concentrations of adiponectin and the 
presence of metabolic syndrome, respectively19. Therefore, we suspect a complex molecular interplay between 
omentin-1 and metabolic conditions regarding cardiovascular health. Intense research and well-designed experi-
ments are needed, addressing the biological cardiovascular processes of omentin-1 with the risk of different major 
cardiovascular endpoints under different metabolic conditions19. Competition for potentially shared signaling 
pathways with different signaling efficiencies would in principle agree with our observations19.
Strengths of the current study include the prospective study design with high follow-up response rate and 
the rigorous case validation, and the availability of high quality data as a result of the standardized procedures 
enabling us to adjust for a large variety of potential confounders. Nevertheless, the present results are limited to 
middle aged Caucasian participants and might not be generalizable to other populations with different ethnic or 
age composition. Furthermore, the present findings are based on single measurement of chemerin and omentin-1 
concentrations. However, in prior analyses we observed high reliability over time for chemerin26 and omentin-127, 
suggesting that a single measurement may provide reliable risk estimates.
In conclusion, we observed that high plasma chemerin concentrations were associated with a higher risk of 
HF. Moreover, the association between omentin-1 and HF risk were modified by prevalent coronary heart disease, 
showing that the shape of association was linear in absence of prevalent CHD and U-shaped in participants with 
pre-existing CHD.
Materials and Methods
Study population. The European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam 
study consists of 16644 women and 10904 men recruited between 1994 and 1998 from the general population 
in Potsdam and surroundings28. During study follow-up, information about incident diseases and other lifestyle 
factors was collected every 2–3 years29. The study was conducted in accordance with the Declaration of Helsinki. 
Participants gave their written informed consent, and study procedures were approved by the Ethics Committee 
of the Medical Association of the State of Brandenburg.
A case-cohort study design was applied, using all incident HF cases and a subcohort of 2500 individuals ran-
domly drawn from all participants of the EPIC-Potsdam study, who provided blood samples (n = 26444). This 
type of study design enables efficient analyses according to time and costs, whereas the results are generalizable 
in the entire cohort30. After exclusion of individuals with prevalent HF (n = 10), missing follow-up data (n = 55), 
inappropriate blood sample (n = 208), missing covariates (n = 74) and unreliable omentin-1 measurements 
(n = 74), the final study population consisted of 212 verified incident HF cases that occurred during 8.2 ± 1.5 
years of follow-up and a subcohort of 2190 participants (overlap: 22 HF cases) (Fig. 2).
Ascertainment of heart failure. HF cases were identified by self-report, death certificates (diagnosis I50 
of International Classification of Diseases, 10th revision), and linkage to the hospital information system of the 
major hospital in the Potsdam area31,32. Additionally, participants with incident myocardial infarction or reported 
drug used typical for HF treatment have been actively enquired for HF31,32. Potential cases were validated by 
attending physicians using medical specific validation form following an established protocol. Confirmed cases 
were classified according to the Guidelines of the European Society of Cardiology (ESC-Guidelines) into definite 
(n = 149), probable (n = 52) and possible HF cases (n = 11)33. Cases were defined as ‘definite’ if two required 
criteria were fulfilled, i.e. presence of typical symptoms and objective evidence of cardiac dysfunction by echo-
cardiography. Cases were characterized as ‘probable’, either if they were not symptomatic but had pathological 
evidence from echocardiogram, or if they were symptomatic but confirmed by other objective evidence (cardiac 
catheter, electrocardiogram, chest x-ray). Cases with less provided information were defined as ‘possible’31,32. 
Only medically verified incident cases of HF were included.
Assessment of exposure and covariates. At baseline, 30 ml of venous blood was taken from each partic-
ipant, processed and stored in tanks of liquid nitrogen at −196 °C or deep freezers at −80 °C28. The concentrations 
of the adipokines, chemerin and omentin-1, were measured with a sandwich ELISA by Biovendor (Brno, Czech 
Republic) at the Institute for Clinical Chemistry and Pathobiochemistry, Otto-von-Guericke University Magdeburg 
(Magdeburg, Germany). Chemerin was measured with intra-assay coefficients of variation (CV) between 5.1% and 
7.0%, inter-assay CVs between 6.9% and 8.3% and a lower limit of detection of 0.1 ng/ml. The intra- and inter-assay 
CV of omentin-1 ranged between 3.2% and 4.1% and between 4.4% and 4.8%, respectively (limit of detection: 0.5 
ng/ml), according to the manufacturer. Concentrations of total cholesterol, HDL-cholesterol, triglycerides and 
hsCRP had been analyzed at the Department of Internal Medicine, University of Tübingen (Tübingen, Germany) 
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and at the Stichting Huisartsen Laboratorium (Breda, The Netherlands). As described elsewhere, NTproBNP was 
measured at the Institute of Clinical Chemistry and Pathobiochemistry, Otto-von-Guericke University Magdeburg 
(Magdeburg, Germany) using a solid-phase, two-site chemiluminescent immunometric assay (IMMULITE 2000 
Systems Analyzers, Siemens)32. Concentrations below the lower limit of detection (20 pg/ml) were set to 10 pg/ml32. 
At baseline, trained personnel took the anthropometric measurements (weight, height) with participants wearing 
light underwear and no shoes with a precision of 0.1 kg and 0.1 cm, respectively. Waist circumference was meas-
ured at the midway between the lower ribs and the iliac crest and hip circumference over the buttocks. Lifestyle 
characteristics, including physical exercise, smoking history or education were documented at baseline by trained 
interviewers during a computer-assisted interview28. History of prevalent hypertension was defined as systolic blood 
pressure >140 mmHg or diastolic blood pressure >90 mmHg or self-reporting of a diagnosis or use of antihyperten-
sive medication. The prevalence of diabetes at baseline was assessed by using information on self-reported diagnosis, 
medication records and dieting behavior. Dietary habits including alcohol consumption were assessed by a validated 
food frequency questionnaire. Participants were classified as having prevalent CHD, if they had either myocardial 
infarction or angina pectoris self-reported prior to recruitment.
Statistical analysis. As depicted in Fig. 2, complete-case analyses were performed using only participants with 
complete data. Analysis of covariance (ANCOVA), adjusted for age and sex, was performed to investigate associations 
between chemerin, omentin-1 concentrations and several cardiovascular risk factors across quartiles of chemerin 
and omentin-1 concentrations within the subcohort. Variables were expressed as adjusted percentage or mean and 
95%-confidence intervals (95%-CI). Correlations between the adipokines chemerin, omentin-1 and general and bio-
chemical characteristics were assessed using Spearman sex- and age-adjusted partial correlation coefficients.
The associations between chemerin, omentin-1 and risk of HF were investigated by calculating hazard ratios 
(HR) and 95%-CI, modified for the case–cohort design according to the Prentice method. Age was used as the 
underlying time variable with entry time defined as the participant’s age at recruitment and exit time defined 
as the age at time of HF diagnosis or censoring. The final multivariable adjusted models included the following 
covariates: age, sex (Model 1), waist circumference, physical activity, education, smoking, alcohol consumption 
(Model 2), prevalent hypertension, diabetes, CHD (Model 3), and HDL-cholesterol, total cholesterol, triglycer-
ides, hsCRP (Model 4). Concentration of triglycerides and hsCRP were natural log transformed. For the investiga-
tion of linear relationships (on a continuous scale) omentin-1 and chemerin were base 2 logarithm transformed, 
enabling the interpretation of increasing HF risk per doubling of values. Further, risk of HF was evaluated accord-
ing to quartiles of the adipokines. The shape of the associations between chemerin, omentin-1 and HF risk in the 
entire sample and in subgroups was determined using restricted cubic spline Cox regression analysis adapted to 
Figure 2. Flow diagram. Flow diagram for the exclusion criteria indicating the number of participants excluded 
from the present study.
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the case-cohort design using five knots at the 5th, 35th, 50th (reference), 65th and 95th percentile of chemerin and 
omentin-1 in the fully adjusted model. The Wald chi-square test was used to evaluate whether a nonlinear term of 
log2-omentin-1 added significant information to the model.
Possible effect modifications between important risk factors for HF (dichotomous) i.e. sex (male/female), obe-
sity (waist circumference women ≤/>88 cm; men ≤/> 102 cm), inflammation (hsCRP </≥1.0 mg/l) and preva-
lent diabetes (yes/no), prevalent hypertension (yes/no), prevalent CHD (yes/no), and omentin-1 (continuous) or 
chemerin (continuous) in relation to HF risk were tested with cross-product terms in the fully adjusted model 4.
Several sensitivity analyses were carried out. We excluded the first 2 years of follow-up (n = 45) to account for 
the latency period between pathology and clinical diagnosis. Moreover, we excluded all probable and possible 
cases (n = 63). Because NT-proBNP has been proposed as an important marker for HF, additional analysis was 
performed with further adjustment of NT-proBNP, using a subsample of 1346 participants with NT-proBNP 
measurements (non-cases = 1141; cases = 205). NT-proBNP was natural log transformed.
The proportional hazard assumption was explored within the subcohort by plotting Schönfeld residuals for 
omentin-1 and chemerin against time. No violation was observed. A p-value < 0.05 was considered to be statistically 
significant. All statistical analyses were performed using SAS software, version 9.4 (SAS institute, Cary, N.C., USA).
Data Availability. The datasets generated during and/or analyzed during the current study are not publicly 
available due to provisions of the written informed consent.
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